Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NASH Companies Take The Stage At AASLD

AASLD Round-Up: NGM, Inventiva, Albireo Among The Companies Progressing In NASH

Executive Summary

NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.

You may also be interested in...



CymaBay Shelves NASH Drug Seladelpar On Liver Safety Concerns

Atypical histological findings from a Phase IIb NASH study lead CymaBay to terminate mid-stage studies in NASH and PSC and place a Phase III PBC trial on hold.

Novartis, Pfizer Advance Their NASH Ambitions Separately, As Partners

Novartis thinks tropifexor may prove to be best-in-class FXR agonist, while Pfizer notes the complementary activity of its ACC and DGAT2 inhibitors. Their NASH trial collaboration is heading toward a Phase II launch in 2020.

Cirius’ Mixed Phase IIb Results In NASH Don’t Quell Its Enthusiasm For Phase III

Privately held biotech plans to move insulin sensitizer into Phase III with ambitious goals of obtaining accelerated approval based on liver histology, while also trying to show long-term cardiovascular benefits.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141197

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel